A single dose of REGEN-COV, a combination monoclonal antibody therapy, reduced the risk of COVID-19 by 81.6% several months after a single dose. UNC School of Medicine’s Myron Cohen, MD, leads monoclonal antibody research efforts as part of the NIH-sponsored COVID Prevention Network.
Regeneron Pharmaceuticals, Inc. announced additional positive results from a phase 3 clinial trial jointly run with the National Institute of Allergy and Infectious Diseases (NIAID), which assessed use of a single dose of investigational REGEN-COV® (1,200 mg administered via 4 subcutaneous injections) to prevent COVID-19 in uninfected individuals. The new analyses show REGEN-COV reduced the risk of contracting COVID-19 by 81.6% during the pre-specified follow-up period (months 2-8), maintaining the risk reduction during the first month after administration, which had been previously reported in The New England Journal of Medicine.
“Today’s new data demonstrate how a single dose of REGEN-COV can help protect people from COVID-19 for many months after administration,” said Myron S. Cohen, MD, who leads the monoclonal antibody efforts for the NIH-sponsored COVID Prevention Network (CoVPN) and is director of the Institute for Global Health & Infectious Diseases at the University of North Carolina at Chapel Hill. “These results demonstrate that REGEN-COV has the potential to provide long-lasting immunity from SARS-CoV-2 infection, a result particularly important to those who do not respond to COVID-19 vaccines including people who are immunocompromised.”
Read more from the UNC Health and UNC School of Medicine Newsroom.